Rethinking Cholesterol: What Centenarians and Emerging Research Tell Us About Longevity and Heart Health

In recent years, the conventional wisdom on cholesterol—that lower is always better—has faced growing scrutiny. A viral discussion sparked by a 2024 study from the Swedish AMORIS cohort has highlighted intriguing patterns: individuals who reach age 100 often had higher total cholesterol levels decades earlier compared to those who didn’t. Combined with other research on the so-called “LDL paradox” and the risks of very low cholesterol, these findings challenge aggressive statin use and prompt a reevaluation of how we approach heart health and longevity.

The Swedish AMORIS Study: Biomarkers of Exceptional Longevity

Published in GeroScience (2024), this large-scale analysis followed 44,636 adults aged 64–99 from the AMORIS cohort, with blood biomarkers measured between 1985–1996 and follow-up extending up to 35 years. Of these, 1,224 (mostly women) reached age 100.

Key findings on biomarkers associated with reaching 100:

• Higher total cholesterol and iron levels were linked to greater odds of centenarian status.
• Lower glucose, creatinine, uric acid, and certain liver enzymes (e.g., GGT, ALP) were also favorable.
• Centenarians showed remarkably homogeneous profiles, suggesting genetic or lifestyle factors visible early in late life.

An important correction to the original paper clarified the cholesterol interpretation: Low total cholesterol (lowest quintile) was associated with reduced likelihood of reaching 100, while high cholesterol neither increased nor decreased the odds. In other words, avoiding very low cholesterol appears protective for longevity, but extremely high levels don’t confer extra benefit here.

This aligns with prior observations that cholesterol needs rise with age for cell repair, hormone production, and immune function. As Dr. Benjamin Bikman, a metabolic researcher, often notes in his lectures and podcasts, cholesterol is essential for mitochondrial health (energy production in cells), steroid hormone synthesis (like testosterone and cortisol), and immune responses. Impairing these via overly aggressive lowering could have unintended consequences.

The “LDL Paradox”: Higher LDL Often Linked to Longer Life in Older Adults

Multiple reviews challenge the idea that high LDL-cholesterol (LDL-C) universally shortens life, especially in the elderly:

• A 2020 analysis of 19 studies involving over 6.3 million people found that higher LDL-C was associated with longer lifespan or neutral mortality in many cohorts. In 9 of 20 cohorts reviewed, those with the highest LDL-C lived longer, regardless of statin use.
• Elderly individuals (>60 years) with high LDL-C often outlive those with low levels, per systematic reviews of 30+ cohorts totaling 68,000+ participants.

This “paradox” may reflect reverse causation (illness lowers cholesterol) or cholesterol’s protective roles against infections, frailty, and cancer—common killers in old age.

Risks of Very Low Cholesterol

Aggressively lowering LDL-C isn’t risk-free:

• A prospective study of ~96,000 participants (published in Neurology, 2019–2020) found LDL-C <70 mg/dL was associated with significantly higher risk of intracerebral hemorrhage (ICH), a deadly form of stroke. Those below 70 mg/dL had ~65% increased ICH risk compared to 70–99 mg/dL.
• Similar patterns hold for hemorrhagic stroke in women and post-ischemic stroke patients.

These risks are particularly relevant for older adults or those on high-intensity statins/PCSK9 inhibitors aiming for ultra-low LDL.

The Ongoing Statin and Guideline Debate

As of 2025–2026, cholesterol guidelines remain in flux:

• Updated European (ESC/EAS 2025) and U.S. (anticipated ACC/AHA 2026) guidelines continue emphasizing LDL lowering but increasingly endorse combination therapies and personalized targets.
• Controversies persist: Some experts argue for starting statins earlier (e.g., age 40 thresholds), while others highlight limited benefits for primary prevention in low-risk groups and potential harms like insulin resistance or mitochondrial dysfunction from statins.
• Influential voices, including metabolic researchers, advocate focusing on insulin sensitivity and metabolic health over blanket LDL reduction.

What This Means for You

Cholesterol is not inherently “bad”—it’s vital for life. While high LDL drives atherosclerosis in younger, metabolically unhealthy people, patterns shift in older age. Prioritizing low glucose (via low-carb diets), good iron balance, and overall metabolic health may better support longevity than chasing ever-lower cholesterol.

Always consult your doctor for personalized advice, especially if considering changes to medications. Emerging research suggests a nuanced view: Optimal cholesterol might be higher than we’ve been told, particularly as we age.

What do you think—has this shifted your perspective on cholesterol? Share in the comments!